First-line therapy with bendamustine/prednisone/bortezomib-A GMMG trial for non-transplant eligible symptomatic multiple myeloma patients.

European Journal of Haematology
Wolfgang KnaufBPV trial group

Abstract

The German-speaking Myeloma Multicenter Group (GMMG) conducted this trial to investigate efficacy and safety of the three-drug combination bendamustine/prednisone/bortezomib (BPV) as first-line therapy for elderly patients with multiple myeloma (MM). Elderly MM patients requiring first-line therapy and not eligible for intensive treatment were enrolled in this phase IIb multicenter study. Patients were treated with BPV regimen for a maximum of nine cycles. Forty-six patients were included in the trial with a median age of 76 years. Nineteen patients had renal impairment at baseline. The ORR was 78.8% for patients treated with 3 and more BPV cycles and 71.1% for all evaluable patients. The median progression-free survival was 25 months, and overall survival at 24 months was 83.3%. The clinical benefit rate including MR was 91.2%. In patients with renal impairment at baseline, a renal response was observed in 11 pts. with complete recovery of the renal function in six patients. The most frequent CTC grade 3/4 AEs experienced by patients were hematological (17.5%) and infectious (9.8%) complications. No new safety signals were observed for the study drugs under investigation. Bendamustine/prednisone/bortezomib may serve as a first...Continue Reading

References

Jul 21, 2006·Leukemia·B G M DurieUNKNOWN International Myeloma Working Group
Feb 20, 2007·Cancer Research·Silke MeisterReinhard E Voll
Dec 12, 2007·Best Practice & Research. Clinical Haematology·M V Mateos, J F San Miguel
Aug 30, 2008·The New England Journal of Medicine·Jesús F San MiguelUNKNOWN VISTA Trial Investigators
Feb 20, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D Cheson, Mathias J Rummel
Oct 20, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Meletios A DimopoulosJésus San Miguel
Feb 5, 2011·Blood·S Vincent RajkumarUNKNOWN International Myeloma Workshop Consensus Panel 1
Nov 28, 2012·Journal of Cancer Research and Clinical Oncology·Wolfram PönischDietger Niederwieser
Jun 20, 2014·Journal of Cancer Research and Clinical Oncology·Wolfram PönischDietger Niederwieser
Dec 3, 2014·The Lancet Oncology·S Vincent RajkumarJesus F San Miguel
Apr 17, 2015·Oncology Research and Treatment·Wolfgang KnaufAndreas Schwarzer
Jun 10, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ruben NiesvizkyJames Reeves
Dec 10, 2017·Hematology·María-Victoria Mateos, Jesús F San Miguel
Dec 13, 2017·The New England Journal of Medicine·María-Victoria MateosUNKNOWN ALCYONE Trial Investigators
Nov 25, 2018·Annals of Hematology·Hartmut GoldschmidtLaurent Garderet
May 30, 2019·The New England Journal of Medicine·Thierry FaconUNKNOWN MAIA Trial Investigators

❮ Previous
Next ❯

Citations

Aug 18, 2020·Biological & Pharmaceutical Bulletin·Mayako UchidaTsutomu Nakamura

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Journal of the American Heart Association
Enayet K ChowdhurySecond Australian National Blood Pressure Study Group <xref ref-type="author-note" rid="jah34572-note-1001"><sup>†</sup></x
Current Opinion in Nephrology and Hypertension
Jennifer E Flythe, Steven M Brunelli
© 2021 Meta ULC. All rights reserved